Revenue
2022
2023
2024
2025
4basebio plc (4BB)
Price£4.80Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £1.7M | £933,000 | £506,000 | £268,000 |
| Gross profit | £974,000 | £630,000 | £340,000 | £239,000 |
| Gross margin | 57.53% | 67.52% | 67.19% | 89.18% |
| Research & development | £5.1M | £4.7M | £2.2M | £2.1M |
| Operating expenses | £18.6M | £12.7M | £8.5M | £5.9M |
| Operating income | −£17.6M | −£12.0M | −£8.2M | −£5.7M |
| Operating margin | −1,039.57% | −1,290.68% | −1,613.83% | −2,115.30% |
| EBITDA | −£15.6M | −£11.0M | −£7.3M | −£5.4M |
| EBITDA margin | −919.73% | −1,175.67% | −1,451.19% | −2,018.28% |
| Net income | −£16.9M | −£12.3M | −£7.7M | −£5.2M |
| Net profit margin | −998.52% | −1,321.86% | −1,514.82% | −1,921.64% |
| Basic EPSper basic share | -£1.09 | -£0.94 | -£0.62 | -£0.42 |
| Diluted EPSper diluted share | -£1.09 | -£0.94 | -£0.62 | -£0.42 |
Community posts
4basebio expands synthetic-DNA manufacturing for personalised mRNA medicines
4basebio announced an expansion of its DNA offering on 7 September 2026. Manufacturing changes The company has added suite capacity and enhanced process controls and quality systems across its Cambridge high-quality and current-GMP operatio ...